Publication in refereed journal
香港中文大学研究人员 ( 现职)
| 杨明明教授 (肿瘤学系) |
| 吕伟欣教授 (生物医学学院) |
全文
| 数位物件识别号 (DOI) http://dx.doi.org/10.2217/FON.11.95 |
引用次数
Web of Sciencehttp://aims.cuhk.edu.hk/converis/portal/Publication/62WOS source URL
其它资讯
摘要Despite recent advances in the understanding of the biologic basis of hepatocellular carcinoma (HCC) development, the clinical management of the disease remains a major challenge. Deregulation of the PI3K/Akt/mTOR pathway, which is a prototypic survival pathway, is increasingly implicated in HCC carcinogenesis. In this article, we detailed the role of this pathway in the pathogenesis of HCC and provide an update on the preclinical and clinical development of various agents targeting this key survival/proliferation pathway, which include various PI3K inhibitors, Akt inhibitors and mTOR inhibitors for HCC. In addition, we highlighted the therapeutic potential of combination strategy for mTOR inhibitors with conventional chemotherapy, in particular, antimicrotubule agents, other molecular targeting agents, as well as radiotherapy.
着者Zhou Q, Lui VWY, Yeo W
期刊名称Future Oncology
出版年份2011
月份10
日期1
卷号7
期次10
出版社Future Medicine
页次1149 - 1167
国际标準期刊号1479-6694
电子国际标準期刊号1744-8301
语言英式英语
关键词combined targeting; hepatocellular carcinoma; PI3K/Akt/mTOR
Web of Science 学科类别Oncology; ONCOLOGY
